ライフサイエンスコーパス: neuron-specific enolase

1 cidic protein) or neurons (synaptophysin and neuron-specific enolase).

2 duced increases in serum S100beta, GFAP, and neuron specific enolase.

3 ation of mitotic activity, and production of neuron-specific enolase.

4 ls were fixed and immunostained for LHRH and neuron-specific enolase.

5 , somatosensory-evoked potentials, and serum neuron-specific enolase.

6 for the determination of microRNA levels and neuron-specific enolase.

7 fibrovascular tissue that did not stain for neuron-specific enolase.

8 ed by a lack of change in MCAv, S100beta and neuron-specific enolase.

9 tin (64 of 66, 97%), desmin (70 of 78, 90%), neuron-specific enolase (60 of 74, 81%), and the EWS-WT1

10 duced expression of neuronal markers such as neuron specific enolase and beta-III tubulin.

11 concentrations peaked earliest, followed by neuron-specific enolase and finally myelin basic protein

12 uced neural morphology and markers including neuron-specific enolase and neurofilament protein.

13 Finally we identified two TMs (neuron-specific enolase and pro-gastrin-releasing peptid

14 Neuron-specific enolase and S-100 levels increased in th

15 Serum neuron-specific enolase and S100b concentrations were in

16 eviously characterized biomarkers, including neuron-specific enolase and S100B protein.

17 al morphology, expressed the neuronal marker neuron specific enolase, and were incorporated into the

18 Enrollment leptin, neuron-specific enolase, and intracellular cell adhesion

19 The baseline levels of chromogranin A, neuron-specific enolase, and multiple soluble angiogenic

20 Preliminary data show that serum S100b, neuron-specific enolase, and myelin basic protein may ai

21 anin A and positive for bombesin, serotonin, neuron-specific enolase, and the c-met protooncogene (a

22 serum biomarkers (matrix metallopeptidase-9, neuron-specific enolase, and vascular cellular adhesion

23 previously reported biomarkers of acute IS (neuron-specific enolase: area under the curve=0.69; inte

24 y can potentially measure injury to neurons (neuron-specific enolase), astrocytes (S100b), and axons

25 As compared to neuron-specific enolase, circulating microRNAs are modes

26 al tau, S-100 calcium-binding protein B, and neuron-specific enolase concentrations in plasma and ser

27 Serum S100 beta (S100B) and neuron-specific enolase concentrations rise after brain

28 acy, defined as the geometric area under the neuron-specific enolase curve from 24 to 72 hours after

29 ignificant differences in the area under the neuron-specific enolase curve, or a composite end point

30 Confounders of neuron-specific enolase elevation should be actively con

31 Performance Category 1-2 had confounders for neuron-specific enolase elevation.

32 ion (STAT) pathway, under the control of the neuron-specific enolase enhancer/promoter.

33 it to target cre to the 3' end of the mouse neuron-specific enolase (Eno2) gene carried on a 250-kb

34 , MUC2, MUC5AC, synaptophysin, chromogranin, neuron specific enolase, epidermal growth factor recepto

35 differences were absent for DAB1,GAD(65) and neuron-specific-enolase expression implying that RELN an

36 tio, 5.58; 95% CI, 2.56-12.16), and elevated neuron-specific enolase (false-positive rate, 0.12; 95%

37 rkers [ie, age, lactate dehydrogenase (LDH), neuron-specific enolase, ferritin, and MYCN gene amplifi

38 icant changes were detected in the levels of neuron-specific enolase from preseason values (median, 6

39 also measured fasting serum chromogranin A, neuron-specific enolase, gastrin, glucagon, vasoactive i

40 corneal reflexes, presence of myoclonus, and neuron-specific enolase greater than 75 microg/L; accura

41 All three patients with neuron-specific enolase greater than 90 mug/L and Cerebr

42 d case reviews of good outcome patients with neuron-specific enolase greater than 90 mug/L and poor o

43 urden, plasma chromogranin A (>/=600 mug/L), neuron-specific enolase (>/=25 mug/L), and classic gradi

44 Using best specificity, serum S100b and neuron-specific enolase had optimal positive and negativ

45 em reflexes in normothermia (p = 0.013), and neuron-specific enolase higher than 33 mug/L (p = 0.029)

46 l and morphology were quantified by studying neuron-specific enolase-immunostained cells at various t

47 ithout any change in messenger RNA levels of neuron-specific enolase in BA 9.

48 tly reduced, independently and as a ratio to neuron-specific enolase, in both prefrontal cortex and h

49 Neuron-specific enolase is an easily available, observer

50 , somatosensory-evoked potentials, and serum neuron-specific enolase, is recommended; however, no stu

51 iate filaments, labeling Muller cells) or to neuron-specific enolase (labeling retinal neurons).

52 emizygotes for the transgenes SYN-LEPR-B and neuron-specific enolase-LEPR B (NSE-LEPR-B).

53 than 90 mug/L and poor outcome patients with neuron-specific enolase less than or equal to 17 mug/L (

54 The majority of 14 patients with neuron-specific enolase less than or equal to 17 mug/L w

55 e score), the tumor burden, and the baseline neuron-specific enolase level.

56 Exenatide did not reduce neuron-specific enolase levels and did not significantly

57 er S100B levels at all time points and lower neuron-specific enolase levels on days 1 and 3 compared

58 s is not associated with neuronal loss since neuron-specific enolase levels were comparable between t

59 fluid biomarkers, such as protein 14-3-3 and neuron-specific enolase, may be useful prognostic indica

60 The level of neuron-specific enolase messenger RNA as a neuronal mark

61 Reelin, GAD(65), GAD(67), DAB1, and neuron-specific-enolase messenger RNAs (mRNAs) and respe

62 RNA expression but not that corresponding to neuron-specific enolase mRNA.

63 r pyramidal in shape, and immunoreactive for neuron-specific enolase, mu opioid receptors, and galani

64 des several neuroendocrine-associated genes (neuron-specific enolase, neurogranin), suggesting that E

65 markers of mature granule neurons including neuron specific enolase, neuronal nuclei, and the calciu

66 illary acidic protein, CD11b), and neuronal (neuron-specific enolase, neuronal nitric oxide synthase)

67 rs progastrin releasing peptide (ProGRP) and neuron specific enolase (NSE) is presented, which involv

68 Serum neuron specific enolase (NSE) measurements, brain imagin

69 Double-labeled immunostaining for MCP-1 and neuron specific enolase (NSE) or glial fibrillary acidic

70 iated virus (rAAV) vectors incorporating the neuron specific enolase (NSE) promoter and either a rat

71 ibitor, noggin, or BMP4 under control of the neuron specific enolase (NSE) promoter.

72 cularly imprinted electrochemical sensor for neuron specific enolase (NSE) was developed by electroch

73 S-100b, neuron specific enolase (NSE), and tau protein were assa

74 lpropyl)imidazolium bromine ionic liquid and neuron specific enolase (NSE).

75 ve for A2B5, CNPase, neurofilament (NF), and neuron specific enolase (NSE).

76 s or astrocytes in transgenic mice using the neuron- specific enolase (NSE) promoter or a modified gl

77 A transgene consisting of 2.8 kb of the rat neuron-specific enolase (NSE) 5' flanking region fused t

78 Serum levels of neuron-specific enolase (NSE) and neuron-enriched S100 b

79 Neuron-specific enolase (NSE) is a biomarker for neurona

80 Neuron-specific enolase (NSE) is a widely-used biomarker

81 Human neuron-specific enolase (NSE) or isozyme gamma has been

82 We have found that antibodies to neuron-specific enolase (NSE) preferentially label a sub

83 (rAAV) vector, pTR-BDNFmyc, incorporated the neuron-specific enolase (NSE) promoter and the internal

84 that overexpresses BMP4 under control of the neuron-specific enolase (NSE) promoter develops a FOP-li

85 was placed under the control of 1.8-kilobase neuron-specific enolase (NSE) promoter for this purpose.

86 anscription factor, under the control of the neuron-specific enolase (NSE) promoter show both markedl

87 apoE isoforms on the brain, we have used the neuron-specific enolase (NSE) promoter to express human

88 d that overexpress BMP4 under control of the neuron-specific enolase (NSE) promoter.

89 Chromogranin A (CgA) and neuron-specific enolase (NSE) were assessed monthly if e

90 rphology and expressed an increased level of neuron-specific enolase (NSE), a classical marker of neu

91 has been successfully used for detection of neuron-specific enolase (NSE), a traumatic brain injury

92 ks were analyzed for the neuromarkers S100B, neuron-specific enolase (NSE), and glial fibrillary acid

93 h the reliability of neurologic examination, neuron-specific enolase (NSE), and median nerve somatose

94 mmunohistochemistry using rabbit antisera to neuron-specific enolase (NSE), tyrosine hydroxylase (TH)

95 cal staining showed that these cells contain neuron-specific enolase (NSE), tyrosine hydroxylase (TH)

96 Serotonin, neuron-specific enolase (NSE), ubiquitin carboxyl termin

97 c mice expressing apoE3 or apoE4 in neurons [neuron-specific enolase (NSE)-apoE] or astrocytes [glial

98 ons, as demonstrated by co-localization with neuron-specific enolase (NSE)-IR, but is especially prom

99 Tau had higher accuracy than serum neuron-specific enolase (NSE; the area under the receive

100 b3J/db3J and db/db mice bearing a transgene (neuron-specific enolase [NSE]-Rb) expressing the B isofo

101 (a total of 137 lactate dehydrogenase and 77 neuron-specific enolase observations), the statistical f

102 equal to 25%, and a baseline plasma level of neuron-specific enolase of greater than 15 ng/mL indepen

103 electroencephalography reactivity, and serum neuron-specific enolase offers the best outcome predicti

104 inal cultures, subsequently characterized by neuron-specific enolase or glial fibrillary acidic prote

105 /chemokine (C-C motif) ligand 2 (p = 0.030), neuron-specific enolase (p = 0.006), and S100b (p = 0.01

106 tivariate analysis, markedly elevated plasma neuron-specific enolase (P = 0.016; hazard ratio, 2.9; 9

107 c activity, and expression of the NE markers neuron-specific enolase, parathyroid hormone-related pep

108 Elevated baseline chromogranin A, neuron-specific enolase, placental growth factor, and so

109 ase elevation should be actively considered: neuron-specific enolase-producing tumors, acute brain di

110 utant ICE-lacZ gene under the control of the neuron specific enolase promoter appeared neurologically

111 overexpressing human DeltaE-torsinA using a neuron specific enolase promoter.

112 g PDGF-A in neurons under the control of the neuron-specific enolase promoter (NSE-PDGF-A) resulted i

113 ying beta-galactosidase under the control of neuron-specific enolase promoter (NSE::LacZ) from the SV

114 hamster PrP from the PrP promoter (tg7), the neuron-specific enolase promoter (tgNSE), or the astrocy

115 , we expressed Fig4 under the control of the neuron-specific enolase promoter and the astrocyte-speci

116 ith a bcl-2 transgene under the control of a neuron-specific enolase promoter have increased numbers

117 ction of expressing soluble NCAM-EC from the neuron-specific enolase promoter in the developing and m

118 signaling in palate development, we used the neuron-specific enolase promoter to express the beta3 su

119 expressing heme oxygenase-1 (HO-1) using the neuron-specific enolase promoter were impaired in learni

120 xpressing the POMC gene under control of the neuron-specific enolase promoter were produced.

121 overexpress noggin under the control of the neuron-specific enolase promoter) or fewer than normal (

122 ne-regulated system under the control of the neuron-specific enolase promoter, of several lines of mi

123 d in neurons cultured from brain cortices of neuron-specific enolase promoter-driven apoE3 (NSE-apoE3

124 3 or apoE4 in the brain under control of the neuron-specific enolase promoter.

125 e overexpressing CatB under the control of a neuron-specific enolase promoter.

126 drogenase 1 (Glud1) under the control of the neuron-specific enolase promoter.

127 P) inhibitor Noggin under the control of the neuron-specific enolase promoter.

128 of transgenic mice under the control of the neuron-specific enolase promoter.

129 or apoE4 in neurons under the control of the neuron-specific enolase promoter.

130 orrelated with 1- and 4-hr postresuscitation neuron-specific enolase (r = -.86, p < .001 and r = -.87

131 Immunostaining for neuron specific enolase revealed that the cultures were

132 th with clinical and biochemical parameters (neuron-specific enolase, S-100).

133 We measured serum neuron-specific enolase, S100b, and myelin basic protein

134 nt protein 1/chemokine (C-C motif) ligand 2, neuron-specific enolase, S100b, intercellular adhesion m

135 A neuron-specific enolase serum concentration greater than

136 An neuron-specific enolase serum concentration less than or

137 We analyzed neuron-specific enolase serum concentrations 3 days afte

138 Neuron-specific enolase serum concentrations less than o

139 High neuron-specific enolase serum concentrations reliably pr

140 uantitative PLR correlated with higher serum neuron-specific enolase (Spearman r = -0.52, p < 0.0001)

141 Receiver operator curves for serum S100b and neuron-specific enolase to classify favorable versus unf

142 added value of the serum biomarkers S100 and neuron-specific enolase to clinical characteristics for

143 ir6.2 mRNA was present in neurons expressing neuron-specific enolase, tyrosine hydroxylase, neuropept

144 le outcome were 2.89 (95% CI, 1.09-7.73) for neuron-specific enolase, using a cutoff of 62.0 ng/mL, a

145 Neuron-specific enolase was an accurate predictor of neu

146 Messenger RNA levels of CREB and neuron-specific enolase were determined in total RNA by

147 osensory evoked potentials (SSEP), and serum neuron-specific enolase were performed in parallel, as p

148 tion, electroencephalography reactivity, and neuron-specific enolase yielded the best predictive perf